Investigational New Drugs

, 26:473

Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma

  • Dennis L. Carter
  • Lina Asmar
  • David Barrera
  • John Caracandas
  • J. Shaker Dakhil
  • Dean McCracken
  • Mark A. O’Rourke
  • Richard K. Rosenberg
  • Kristi A. Boehm
  • Des Ilegbodu
  • Robert L. Reid
PHASE II STUDIES

Summary

Purpose: Several trials have demonstrated the superiority of simultaneous chemoradiotherapy compared with radiation alone for patients with locally advanced head and neck cancers. However, the optimal regimen remains to be defined. This study assessed the safety and activity of combined carboplatin (C), paclitaxel (P), and twice-daily radiotherapy (RT) in a community based, multicenter, phase II trial. Materials and Methods: Eligible patients (N = 52) had ECOG PS 0–2 and previously untreated, stage III or IV (M0), unresectable, squamous cell cancers of the head and neck. Treatment consisted of 6 weekly courses of C (AUC = 1), P (40 mg/m2/1-h) and twice-daily radiation (120 cGy BID; total dose of 6,960 cGy). Subsequently, patients with N2/N3 disease were permitted neck dissection. Results: Median follow-up was 61 months. Sixty-seven percent (67%) of patients had stage IV (M0) disease at baseline. Fifty-five percent (55%) of treated patients experienced NCI Grade 3–4 dysphagia, stomatitis, or mucositis; 80% had ≥Grade 3 toxicity of any organ system. Median weight loss was 7.1 lbs; 35% of patients experienced 10% or more weight loss. Of 43 patients evaluable for response, responses were: 29 CR (67%), 7 PR (16%), 1 MR (2%), 4 SD (9%), and 2 PD (5%); the overall response rate (CR+PR) was 84%. For the entire cohort of 52 patients, the estimated overall survival at 36 months was 60%; progression-free survival was 50%. Conclusions: We conclude that weekly C + P and concurrent twice-daily hyperfractionated radiotherapy is tolerated and highly active in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck.

Keywords

Cancer Chemotherapy Radiation Concurrent Hyperfractionated 

References

  1. 1.
    American Cancer Society. Cancer facts and figures 2007. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_1x_What_are_the_key_statistics_for_oral_cavity_and_oropharyngeal_cancer_60.asp? siteria= (accessed April 7, 2008)
  2. 2.
    Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA (1996) Familial risks of squamous cell carcinoma of the head and neck: retrospective case–control study. BMJ 313(7059):716–721PubMedGoogle Scholar
  3. 3.
    Prout MN, Sidari JN, Witzburg RA, Grillone GA, Vaughan CW (1997) Head and neck cancer screening among 4611 tobacco users older than forty years. Otolaryngol Head Neck Surg 116(2):201–208PubMedCrossRefGoogle Scholar
  4. 4.
    Maier H, Dietz A, Gewelke U, Heller WD, Weidauer H (1993) Tobacco and alcohol and the risk of head and neck cancer. Clin Invest 70(3–4):320–327Google Scholar
  5. 5.
    Yokoyama A, Omori T (2003) Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers. Jpn J Clin Oncol 33(3):111–121PubMedCrossRefGoogle Scholar
  6. 6.
    Boffetta P, Ye W, Adami HO, Mucci LA, Nyren O (2001) Risk of cancers of the lung, head and neck in patients hospitalized for alcoholism in Sweden. Br J Cancer 85(5):678–682PubMedCrossRefGoogle Scholar
  7. 7.
    Mork J, Lie AK, Glattre E et al (2001) Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344(15):1125–1131PubMedCrossRefGoogle Scholar
  8. 8.
    Yoo HJ, Sepkovic DW, Bradlow HL, Yu GP, Sirilian HV, Schantz SP (2001) Estrogen metabolism as a risk factor for head and neck cancer. Otolaryngol Head Neck Surg 124(3):241–247PubMedCrossRefGoogle Scholar
  9. 9.
    Goldenberg D, Golz A, Joachims HZ (2003) The beverage mate: a risk factor for cancer of the head and neck. Head Neck 25(7):595–601PubMedCrossRefGoogle Scholar
  10. 10.
    Horiot JC, Le Fur R, N’Guyen T et al (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25(4):231–241PubMedCrossRefGoogle Scholar
  11. 11.
    Fu KK, Pajak TF, Trotti A et al (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48(1):7–16PubMedCrossRefGoogle Scholar
  12. 12.
    Overgaard J, Hansen HS, Specht L et al (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362(9388):933–940PubMedCrossRefGoogle Scholar
  13. 13.
    Pignon JP, Baujat B, Bourhis J (2005) Individual patient data meta-analysis in head and neck carcinoma: What have we learnt? Cancer Radiother 9(1):31–36PubMedGoogle Scholar
  14. 14.
    Brizel DM, Albers ME, Fisher SR et al (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798–1804PubMedCrossRefGoogle Scholar
  15. 15.
    Bensadoun RJ, Bénézery K, Dassonville O et al (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 64(4):983–994PubMedGoogle Scholar
  16. 16.
    Budach VG, Stuschke M, Haake K et al (2000) Accelerated chemoradiation to 70.6 Gy is more effective than accelerated radiation to 77.6 Gy alone: two year results of a German multicenter randomized trial. Int J Radiat Oncol Biol Phys 48(Suppl):150Google Scholar
  17. 17.
    Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil–mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial. J Clin Oncol 23:1125–1135PubMedCrossRefGoogle Scholar
  18. 18.
    Huguenin P, Beer KT, Allal A et al (2004) Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 22:4665–4673PubMedCrossRefGoogle Scholar
  19. 19.
    World Health Organization (1979) WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication no. 48. WHO, Geneva, SwitzerlandGoogle Scholar
  20. 20.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. JASA 53:457–481Google Scholar
  21. 21.
    Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578PubMedCrossRefGoogle Scholar
  22. 22.
    Curran D, Giralt J, Harari PM et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25(16):2191–2197PubMedCrossRefGoogle Scholar
  23. 23.
    Fornari G, Artusio E, Mairone L (2002) Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma. Tumori 88(6):489–494PubMedGoogle Scholar
  24. 24.
    Hainsworth JD, Meluch AA, McClurkan S et al (2002) Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 8(4):311–321PubMedCrossRefGoogle Scholar
  25. 25.
    Shin DM, Glisson BS, Khuri FR et al (2002) Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95(2):322–330PubMedCrossRefGoogle Scholar
  26. 26.
    Arnold SM, Regine WF, Ahmed MM et al (2004) Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous sell carcinoma of the head and neck: results of a new treatment paradigm. Int J Radiat Oncol Biol Phys 58(5):1411–1417PubMedCrossRefGoogle Scholar
  27. 27.
    Meluch AA, Greco FA, Gray JR et al (2003) Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Network phase II trial. Cancer J 9(4):251–260PubMedCrossRefGoogle Scholar
  28. 28.
    Meluch AA, Hainsworth JD, Gray JR et al (1999) Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 5(2):84–91PubMedGoogle Scholar
  29. 29.
    Semrau R, Mueller RP, Stuetzer H et al (2006) Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 64(5):1308–1316PubMedGoogle Scholar
  30. 30.
    Kuhnt T, Becker A, Bloching M et al (2006) Phase II trial of simultaneous radiochemotherapy with cisplatinum and paclitaxel in combination with hyperfractionated–accelerated radiotherapy in locally advanced head and neck cancer. Med Oncol 23(3):325–334PubMedCrossRefGoogle Scholar
  31. 31.
    Abitbol A, Abdel-Wahab M, Lewin A et al (2002) Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel; (Taxol) in stage II and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-3 protocol. Int J Radiat Oncol Biol Phys 53(4):942–947PubMedGoogle Scholar
  32. 32.
    Abitbol A, Abdel-Wahab M, Harvey M et al (2005) Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel; (Taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol. Am J Clin Oncol 28(5):449–455PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Dennis L. Carter
    • 1
    • 2
  • Lina Asmar
    • 1
  • David Barrera
    • 1
  • John Caracandas
    • 1
  • J. Shaker Dakhil
    • 1
  • Dean McCracken
    • 1
  • Mark A. O’Rourke
    • 1
  • Richard K. Rosenberg
    • 1
  • Kristi A. Boehm
    • 1
  • Des Ilegbodu
    • 1
  • Robert L. Reid
    • 1
  1. 1.US Oncology Research, Inc.HoustonUSA
  2. 2.Rocky Mountain Cancer CentersAuroraUSA

Personalised recommendations